Inside the Sample Lifecycle: How Central Labs Protect Data from Collection to Analysis

Introduction: Samples as the Foundation of Data

In drug discovery and clinical research, biological samples are not simply physical materials, they are the foundation of data generation. Every data point used to support preclinical decisions or regulatory submissions originates from a sample that has undergone a complex journey.¹ From the moment of collection through to final analysis, each stage in this lifecycle introduces potential risks to data integrity. Central laboratories play a critical role in mitigating these risks by implementing tightly controlled workflows, integrating digital systems, and ensuring end-to-end traceability.²

Understanding how data is protected requires a lifecycle perspective. A typical sample journey begins at the clinical or preclinical collection site, followed by labelling, transportation, accessioning, storage, processing, and ultimately analysis and reporting.³ At each step, both the physical sample and its associated metadata must remain intact, accurate, and fully traceable.

Data Integrity and the ALCOA+ Framework

Regulatory frameworks define data integrity through the ALCOA+ principles, which require data to be attributable, legible, contemporaneous, original, and accurate, as well as complete, consistent, enduring, and available.⁴ These principles underpin how central laboratories design and operate their systems, ensuring that data generated from biological samples can withstand regulatory scrutiny.

Maintaining these standards requires more than careful documentation; it depends on the integration of processes, technologies, and oversight mechanisms that collectively protect both the sample and the data it generates throughout its lifecycle.

Chain of Custody: Ensuring Traceability

A key mechanism supporting data integrity is chain of custody, which refers to the continuous, documented record of a sample’s handling, movement, and storage conditions. Every interaction with the sample, whether during collection, transfer, processing, or analysis, must be recorded with precise details of who performed the action, when it occurred, and under what conditions.⁵

This level of documentation ensures traceability and accountability, while also protecting against risks such as misidentification, contamination, or tampering. Without a robust chain of custody, even high-quality analytical data may be compromised if there is uncertainty surrounding how the sample was handled.

Standardising Collection to Reduce Variability

The lifecycle begins at collection, where variability is often highest due to differences across sites, operators, and environments. Central laboratories address this challenge by providing standardised collection kits and detailed protocols tailored to specific study requirements.⁶

These kits typically include pre-labelled consumables and clear instructions, ensuring that samples are collected consistently regardless of location. By reducing variability at this earliest stage, central labs establish a strong foundation for downstream data quality and reproducibility.

Sample Identification and Metadata Capture

Following collection, accurate sample identification becomes essential. Each sample must be uniquely linked to its corresponding metadata, including subject information, collection timepoints, and sample type. This is typically achieved through barcode-based systems integrated with Laboratory Information Management Systems (LIMS)⁷.

Real-time data capture ensures that information is recorded contemporaneously and remains accessible throughout the study. Errors at this stage, such as incorrect labelling or incomplete metadata, can propagate throughout the lifecycle, making early accuracy critical to maintaining data integrity.

Controlled Logistics and Transport Conditions

Transportation represents a key vulnerability, particularly for temperature-sensitive biological materials. Central laboratories mitigate these risks through validated shipping systems, real-time tracking, and predefined stability criteria.

Samples are transported in controlled environments designed to maintain specific temperature ranges, with continuous monitoring to detect any deviations. Even minor excursions can alter the biological state of a sample, potentially impacting analytical results, making transport conditions a critical component of the overall data integrity framework.⁸

Accessioning and Secure Storage

Upon arrival at the central laboratory, samples undergo accessioning, a process that verifies their identity, condition, and compliance with study requirements. This step acts as a critical checkpoint, ensuring that any discrepancies are identified before analysis begins.

Samples are then logged into LIMS, processed and transferred to controlled storage environments, where conditions such as temperature and humidity are continuously monitored. These systems often include automated alerts and audit trails, ensuring that any deviations are immediately detected and recorded as part of the sample’s lifecycle history.⁹

Standardised Processing and Analysis

The analytical phase is where samples are transformed into data, and central laboratories play a key role in ensuring that this transformation is both accurate and reproducible. By standardising instrumentation, methodologies, and operating procedures, central labs minimise variability and ensure consistency across samples and studies.¹⁰

Validated assays, combined with controlled workflows and trained personnel, ensure that analytical outputs are reliable and comparable. Automation further reduces the risk of human error, while controlled access to samples and laboratory areas limits opportunities for contamination or mishandling.

Data Integrity, Audit Trails, and Reporting

Once data is generated, the focus shifts to ensuring its integrity, traceability, and regulatory compliance. Electronic data capture systems, often designed to meet requirements such as 21 CFR Part 11 (USA) or GDPR (Europe), provide secure environments for data storage and management.¹¹

These systems incorporate audit trails that document every modification, ensuring transparency and accountability. Emerging digital approaches are also being explored to further strengthen data integrity, including technologies designed to create immutable records of sample handling and analysis.

The Value of Centralised Laboratory Oversight

Central laboratories offer a unique advantage by integrating all stages of the sample lifecycle within a single, controlled framework. This centralisation reduces variability, enhances oversight, and ensures that both samples and data are managed consistently across studies.¹²

It also facilitates compliance with global regulatory standards, which require not only robust data but also clear documentation of how that data was generated. By aligning processes across sites and timepoints, central labs enable more reliable and reproducible outcomes.

Conclusion: From Sample to Insight

The integrity of scientific data is inseparable from the integrity of the sample itself. Each step in the lifecycle must be carefully controlled, documented, and traceable to ensure that the resulting data is both scientifically valid and regulatory-ready.

Central laboratories act as custodians of this process, embedding quality and consistency into every stage. As drug development becomes increasingly data-driven, the importance of robust sample lifecycle management will continue to grow, reinforcing the central role of laboratories in delivering reliable, decision-critical insights.

References:

1. Corporation, PHC. “Biological Samples and Their Role in Modern Research: Solution: Phcbi.” PHC Holdings Corporation, www.phchd.com/apac/biomedical/service-downloads/evolving-science-for-the-future/biological-samples-storage-techniques. Accessed 10 Apr. 2026.
2. The 5 Stages of Data Lifecycle Management | Datamation, www.datamation.com/big-data/data-lifecycle-phases/. Accessed 10 Apr. 2026.
3. Sop25-Sample-Processing-and-Storage- ..., www.nhsfife.org/media/95uie39n/sop25-sample-processing-and-storage-v4-final.pdf. Accessed 10 Apr. 2026.
4. “Alcoa & Alcoa+ Principles Explained: Pharma Data Integrity Guide.” TotalLab, 26 Mar. 2026, totallab.com/resources/alcoa-principles/.
5. Highley, Tori. “Clinical Research: Improving Data Management & Reporting with LabKey.” LabKey Software, 3 Nov. 2025, www.labkey.com/chain-of-custody-laboratory/.
6. “Central Laboratory Services.” SGSCorp, SGS, www.sgs.com/en-gb/services/central-laboratory-services. Accessed 10 Apr. 2026.
7. “Ultimate Guide to Lab Sample Management: Best Practices.” Quality Institute of America (QIA), www.qi-a.com/learning-center/lab-sample-management-guide/. Accessed 10 Apr. 2026.
8. Yelimeshyn, Sergey. “Transporting Biological Samples: Ensuring Integrity.” Bostonmedsupply, 19 Feb. 2025, bostonmedsupply.com/transporting-biological-samples-ensuring-integrity-in-extreme-conditions/.
9. Chauhan, Ayush. “Sample Accessioning in Clinical Labs: Best Practices and Procedures.” Flabslis.Com, flabslis.com/blogs/sample-accessioning-in-clinical-labs. Accessed 10 Apr. 2026.
10. Emily Carter, BS. “The Analytical Stage in Lab Testing: Techniques, Importance, and Process.” Needle.Tube - Diagnostic Lab Supplies, Great Prices, Fast Delivery, Blood Collection Needles, Blood Collection Tubes, Infusion Needles, Needle.Tube - Diagnostic Lab Supplies, Great Prices, Fast Delivery, Blood Collection Needles, Blood Collection Tubes, Infusion Needles, 15 Apr. 2025, www.needle.tube/resources-9/the-analytical-stage-in-lab-testing-techniques-importance-and-process.
11. Guideline-Computerised-Systems-and-Electronic-Data-Clinical ..., www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf. Accessed 10 Apr. 2026.
12. PhD, Michael Smith, and Michael Smith PhD Blog Writer. “Understanding What Is Central Lab in Clinical Trials - Solix EAI Pharma.” Solix Pharma, 12 Jan. 2026, pharma.solix.com/learning/understanding-what-is-central-lab-in-clinical-trials/.